227 related articles for article (PubMed ID: 23469454)
1. Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
Coyne DW
Nephrol News Issues; 2013 Feb; 27(2):16, 18, 20. PubMed ID: 23469454
[No Abstract] [Full Text] [Related]
2. The KDIGO anemia guideline: can reason triumph over regulation?
Wish JB
Nephrol News Issues; 2012 Dec; 26(13):20, 22-3. PubMed ID: 23346853
[No Abstract] [Full Text] [Related]
3. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
4. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
5. Recombinant erythropoietin. The effect of the marketplace on socialized patient care.
Besarab A; Erslev AJ
ASAIO J; 1993; 39(2):85-6. PubMed ID: 8324265
[No Abstract] [Full Text] [Related]
6. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
7. Erythropoietin claims monitoring policy: implications for clinical practice.
Messana T
Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
[TBL] [Abstract][Full Text] [Related]
8. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
9. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
10. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.
Ofsthun NJ; Lazarus JM
Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
Messana T
Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
[TBL] [Abstract][Full Text] [Related]
12. Perpetuating sub-optimal care: CMS, QIPs, and the hemoglobin myth.
Pollak SP; Lorch JA; Pollak VE
Nephrol News Issues; 2012 Jan; 26(1):30, 32-4. PubMed ID: 22359963
[TBL] [Abstract][Full Text] [Related]
13. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
Kliger AS; Foley RN; Goldfarb DS; Goldstein SL; Johansen K; Singh A; Szczech L
Am J Kidney Dis; 2013 Nov; 62(5):849-59. PubMed ID: 23891356
[TBL] [Abstract][Full Text] [Related]
14. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
Fishbane S; Jhaveri KD
Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of anemia in chronically dialyzed patients].
Moynot A
Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
[No Abstract] [Full Text] [Related]
16. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
Moist LM; Troyanov S; White CT; Wazny LD; Wilson JA; McFarlane P; Harwood L; Sood MM; Soroka SD; Bass A; Manns BJ
Am J Kidney Dis; 2013 Nov; 62(5):860-73. PubMed ID: 24054466
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
Sobota JT
Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
[No Abstract] [Full Text] [Related]
18. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
Lundin AP
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
[TBL] [Abstract][Full Text] [Related]
19. [Countermeasure for patients with anemia due to hemodialysis].
Suzuki M
Nihon Naika Gakkai Zasshi; 1995 Oct; 84(10):1663-7. PubMed ID: 8537721
[No Abstract] [Full Text] [Related]
20. Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism.
Garcia-Canton C; Palomar R; Moreno A; Toledo A; Suria S; Esparza N; Rossique P; Checa MD
Nephron; 1996; 74(2):444-5. PubMed ID: 8893180
[No Abstract] [Full Text] [Related]
[Next] [New Search]
